company decision

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)

Inclusion Criteria:

• PTSD (DSM-5 criteria)
• Stable allowed medications with no planned changes from 30 days prior to screening through study participation
• Willing to use highly effective birth control
• Willing to comply with protocol visits and procedures

Exclusion Criteria:

• Moderate to severe traumatic brain injury
• Other psychiatric disorders (based on SCID-5-CT) or neurodegenerative disorders
• Substance use disorder or alcohol use disorder within 6 months prior to screening
• Psychotherapy or cognitive based therapy within 30 days prior to screening
• Use of investigational drug within 30 days prior to screening
• Prior participation in study of NYX-783, NYX-2925 or NYX-458.